Chromocell Therapeutics Corporation (CHRO) — Financial Flexibility Index
Chromocell Therapeutics Corporation (CHRO) has a Financial Flexibility Index of -0.06x as of June 2025. Free cash flow of $-447.14K (operating CF $-447.14K minus capex $0.00) represents 0% of total liabilities ($7.32 Million). Check CHRO tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Chromocell Therapeutics Corporation Financial Flexibility Index (2020–2024)
Historical Financial Flexibility Index trend for Chromocell Therapeutics Corporation across 9 annual periods. For the full cash flow conversion analysis, see Chromocell Therapeutics Corporation cash flow conversion.
Annual Financial Flexibility Index for Chromocell Therapeutics Corporation (2020–2024)
Year-by-year free cash flow to debt coverage for Chromocell Therapeutics Corporation. Explore how well can Chromocell Therapeutics Corporation service its debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.42x | $-5.79 Million | $-5.79 Million | $4.08 Million | ▼ -845.9% |
| 2023 | -0.15x | $-981.03K | $-981.03K | $6.54 Million | ▲ +0.0% |
| 2023 | -0.15x | $-981.03K | $-981.03K | $6.54 Million | ▲ +64.0% |
| 2022 | -0.42x | $-1.57 Million | $-1.57 Million | $3.76 Million | ▲ +0.0% |
| 2022 | -0.42x | $-1.57 Million | $-1.57 Million | $3.76 Million | ▲ +3.8% |
| 2021 | -0.43x | $-1.59 Million | $-1.59 Million | $3.68 Million | ▲ +0.0% |
| 2021 | -0.43x | $-1.59 Million | $-1.59 Million | $3.68 Million | ▲ +56.4% |
| 2020 | -0.99x | $-3.63 Million | $-3.63 Million | $3.65 Million | ▲ +0.0% |
| 2020 | -0.99x | $-3.63 Million | $-3.63 Million | $3.65 Million | — |